Show simple item record

dc.contributor.authorTedeschi, A.
dc.contributor.authorTrotman, J.
dc.contributor.authorZinzani, P.
dc.contributor.authorCavallo, F.
dc.contributor.authorMarasca, R.
dc.contributor.authorLiberati, A.
dc.contributor.authorLinton, Kim M
dc.contributor.authorMcKay, P.
dc.contributor.authorHu, B.
dc.contributor.authorColeman, M.
dc.contributor.authorArdeshna, K.
dc.contributor.authorBijou, F.
dc.contributor.authorMarcus, R.
dc.contributor.authorPortell, C.
dc.contributor.authorThieblemont, C.
dc.contributor.authorBachy, E.
dc.contributor.authorCostello, R.
dc.contributor.authorIyengar, S.
dc.contributor.authorMocikova, H.
dc.contributor.authorCo, M.
dc.contributor.authorLi, X.
dc.contributor.authorZhou, W.
dc.contributor.authorCappellini, M.
dc.contributor.authorTankersley, C.
dc.contributor.authorHuang, J.
dc.contributor.authorOpat, S.
dc.date.accessioned2022-01-11T12:00:17Z
dc.date.available2022-01-11T12:00:17Z
dc.date.issued2021en
dc.identifier.citationTedeschi A, Trotman J, Zinzani P, Cavallo F, Marasca R, Liberati A, et al. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). Haematologica. 2021;106(10):35-.en
dc.identifier.urihttp://hdl.handle.net/10541/624991
dc.titleSafety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (magnolia phase 2 study)en
dc.typeArticleen
dc.contributor.departmentASST Grande Ospedale Metropolitano Niguarda;en
dc.identifier.journalHaematologicaen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record